Trastuzumab

證據等級: L5

預測適應症: 10 個

Trastuzumab: From HER2-Positive Breast Cancer to Progesterone Receptor-Positive Breast Cancer

One-Sentence Summary

Trastuzumab (Herceptin) is an internationally established humanized monoclonal antibody targeting HER2, approved for the treatment of HER2-overexpressing breast cancer and gastric/gastroesophageal junction cancer across multiple major regulatory jurisdictions. The TxGNN model predicts it may be specifically effective for Progesterone Receptor-Positive (PR+) Breast Cancer, with 36 registered clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	HER2-positive breast cancer; HER2-positive gastric/gastroesophageal junction cancer (international approval; not registered in the Philippines)
Predicted New Indication	Progesterone Receptor-Positive Breast Cancer
TxGNN Prediction Score	99.90%
Evidence Level	L1
Philippines Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Trastuzumab is a humanized IgG1 monoclonal antibody that targets extracellular domain IV of HER2 (ErbB2), blocking HER2-HER3 dimerization and suppressing downstream PI3K/AKT proliferative signaling. In parallel, trastuzumab recruits natural killer cells via its Fc region to trigger antibody-dependent cell-mediated cytotoxicity (ADCC), directly eliminating HER2-overexpressing tumor cells through immune engagement.

Among PR-positive breast cancers, approximately 15–20% co-overexpress HER2, forming what is clinically recognized as the HR+/HER2+ or “triple-positive” molecular subtype (ER+/PR+/HER2+). This subtype poses a unique biological challenge: HER2 activation can transcriptionally suppress PR expression through phosphorylation of ER-coactivators, while residual PR and ER signaling may attenuate HER2-targeted therapy sensitivity by sustaining alternative survival pathways. A 2024 preclinical study (PMID 38034484) directly demonstrated that the combination of progesterone and estradiol reverses trastuzumab’s inhibitory effect on BT474 triple-positive breast cancer cells, mechanistically explaining why this subtype requires tailored co-targeting strategies.

The TxGNN prediction is further supported by established clinical trial data. The Phase II trial NCT00134680 enrolled patients with ErbB2+/PR+/ER+ metastatic breast cancer receiving letrozole plus trastuzumab — precisely the target population described here — and demonstrated clinical activity. The Phase III RCT NCT01275677 (n=3,270) enrolled node-positive HER2+ patients, a substantial fraction of whom were PR+, providing direct population-level evidence. The WSG-TP-II trial additionally compared endocrine therapy combined with trastuzumab and pertuzumab against de-escalated chemotherapy specifically in the HR+/HER2+ early breast cancer setting, further validating the mechanistic convergence of HER2 blockade and hormone receptor modulation in PR+ disease.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00134680	Phase 2	Completed	33	Letrozole 2.5 mg/day + trastuzumab weekly in ErbB2+/PR+/ER+ metastatic BC — the most directly targeted trial for this indication; evaluated the anti-tumor efficacy and tolerability of combining HER2 blockade with aromatase inhibition in the exact PR+/HER2+ population
NCT01275677	Phase 3	Completed	3,270	Large RCT of adjuvant chemotherapy alone vs. chemotherapy + trastuzumab in node-positive or high-risk HER2-low/HER2+ invasive BC; encompasses PR+ subpopulation and establishes trastuzumab’s adjuvant benefit in HER2-overexpressing disease
NCT00005970	Phase 3	Completed	3,436	AC followed by weekly paclitaxel with or without trastuzumab as adjuvant treatment in HER2-overexpressing breast cancer; landmark trial demonstrating OS and DFS benefit of trastuzumab in the HER2+ population, including HR+ subgroups
NCT00667251	Phase 3	Completed	652	Taxane-based chemotherapy plus lapatinib vs. taxane plus trastuzumab as first-line therapy in HER2+ metastatic BC; directly compared two HER2-targeted strategies and defined trastuzumab as the preferred HER2 agent in this setting
NCT04629846	Phase 3	Completed	517	Pertuzumab biosimilar QL1209 vs. reference pertuzumab, each combined with trastuzumab + docetaxel in HER2+ early or locally advanced BC; validates trastuzumab efficacy consistency as backbone therapy
NCT03726879	Phase 3	Completed	454	IMpassion050: atezolizumab or placebo combined with neoadjuvant AC followed by paclitaxel + trastuzumab + pertuzumab in early HER2+ BC; assessed whether immune checkpoint inhibition adds benefit to the HER2-blockade backbone
NCT04886531	Phase 2	Recruiting	30	Neratinib + aromatase inhibitor + trastuzumab for 24 weeks as neoadjuvant therapy in ER+/HER2+ cancer; chemotherapy-free approach combining HER2 and endocrine co-targeting, directly relevant to the PR+ context
NCT02152943	Phase 1	Completed	37	Everolimus + letrozole + trastuzumab in HR+/HER2+ advanced BC or other solid tumors; explored triple-pathway inhibition (mTOR + ER + HER2) to overcome resistance mechanisms prevalent in PR+/HER2+ disease
NCT04334330	Phase 2	Unknown	34	Palbociclib + trastuzumab + pyrotinib + fulvestrant in ER/PR+/HER2+ BC with brain metastases; evaluates quadruple-targeted approach for the PR+/HER2+ subtype in a CNS disease setting
NCT01785420	Phase 3	Recruiting	1,100	Double-blind RCT of short-duration preoperative trastuzumab vs. placebo in HER2/erbB2-positive operable BC; explores early biological effects of trastuzumab including immune activation (ADCC) prior to definitive surgery

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31410192	2019	Translational Cohort	Theranostics	Multi-omics landscape analysis (n=32,056 SEER + 4 clinical cohorts) of ER+/PR+/HER2+ triple-positive breast cancer; characterized trastuzumab responsiveness and molecular features unique to this subtype — most directly relevant paper for this repurposing prediction
37166817	2023	RCT	JAMA Oncology	WSG-TP-II trial: prospective comparison of endocrine therapy + trastuzumab + pertuzumab vs. de-escalated chemotherapy as neoadjuvant treatment in HR+/HER2+ early BC; first prospective head-to-head evaluation of chemotherapy-free HER2 + endocrine strategy in PR+ disease
32353342	2020	Phase 2 RCT	Lancet Oncology	monarcHER: abemaciclib + trastuzumab ± fulvestrant vs. standard chemotherapy + trastuzumab in HR+/HER2+ advanced BC; demonstrated superior PFS with CDK4/6 inhibition combined with trastuzumab-based endocrine therapy, supporting chemotherapy-free strategies in PR+ subtype
34983437	2022	Retrospective	BMC Cancer	Single-center retrospective study of trastuzumab + fulvestrant combination in HR+/HER2+ advanced BC; provided real-world evidence for the anti-HER2 plus selective estrogen receptor degrader approach applicable to PR+ patients
38034484	2024	Preclinical	Oncology Letters	Progesterone + estradiol combination reverses trastuzumab’s anti-proliferative effect in BT474 triple-positive BC cells; mechanistic evidence for PR-HER2 pathway crosstalk and its implications for optimizing trastuzumab therapy in PR+ disease
27179402	2016	Phase 2 RCT	Lancet Oncology	NeoSphere 5-year analysis: neoadjuvant pertuzumab + trastuzumab + docetaxel vs. controls in locally advanced or early HER2+ BC; 5-year PFS and DFS data confirming durability of dual HER2 blockade benefit
26874901	2016	Phase 3 RCT	Lancet Oncology	ExteNET: 12 months of neratinib after trastuzumab-based adjuvant therapy in HER2+ early BC (n=2,840); HR+ subgroup derived greater benefit from extended HER2 blockade, underscoring the importance of PR/ER status in HER2-targeted therapy optimization
40339592	2025	Phase 2a	Lancet Oncology	Zanidatamab (HER2 bispecific antibody) + palbociclib + fulvestrant in previously treated HR+/HER2+ metastatic BC; antitumor activity in PR+ subset provides contemporary proof-of-concept for combined HER2 + CDK4/6 + endocrine strategy
35640077	2022	Guidelines	JCO	ASCO guideline update on systemic therapy for HER2+ advanced breast cancer; contextualizes trastuzumab’s role across hormone receptor subgroups (including PR+) and provides evidence-based treatment sequencing recommendations
28945833	2017	Phase 2 RCT	Annals of Oncology	WSG-ADAPT HER2+/HR- trial: 12 weeks of neoadjuvant dual blockade (trastuzumab + pertuzumab ± paclitaxel) with pCR as primary endpoint; provided molecular stratification insights distinguishing HR- from HR+ (including PR+) HER2+ subtype responses

Philippines Market Information

Trastuzumab currently has no registered products with the Philippine FDA. The drug has not been approved or marketed in the Philippines as of the data cutoff date.

For international reference, trastuzumab (originator product Herceptin®, Roche/Genentech) holds regulatory approval in:

USA (FDA): HER2-overexpressing breast cancer (adjuvant and metastatic); HER2-overexpressing metastatic gastric/GEJ adenocarcinoma
EU (EMA): Early and metastatic HER2+ breast cancer; HER2+ metastatic gastric cancer
Japan (PMDA): HER2+ breast cancer; HER2+ gastric cancer

Multiple biosimilar products (e.g., QL1701, HD201, SB3) have also received approvals in various jurisdictions, potentially offering a more accessible market entry pathway.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — Humanized anti-HER2 IgG1 monoclonal antibody; not a conventional cytotoxic agent
Myelosuppression Risk	Low (trastuzumab monotherapy rarely causes significant myelosuppression; mild neutropenia reported when combined with cytotoxic chemotherapy)
Emetogenicity Classification	Low
Monitoring Items	Left ventricular ejection fraction (LVEF) before initiation and at regular intervals during treatment (cardiac toxicity is the primary concern); CBC with differential when combined with chemotherapy; liver and renal function
Handling Protection	Standard biologic/monoclonal antibody handling protocols; not classified as a hazardous cytotoxic drug by NIOSH; institutional policies for biologic agent preparation and administration apply

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA-approved prescribing information (or EMA/FDA SmPC) download is recommended to complete the baseline safety assessment for this candidate. Known class-level concerns include cardiotoxicity (symptomatic and asymptomatic LVEF decline), infusion-related reactions, and embryo-fetal toxicity; these should be reviewed before clinical application planning.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Trastuzumab already carries L1-level clinical evidence across multiple completed Phase III RCTs in HER2-positive breast cancer populations that encompass PR+ patients; dedicated studies in the HR+/HER2+ (triple-positive) molecular subtype directly validate both the biological rationale and clinical benefit of HER2 blockade in PR-expressing disease. The TxGNN score of 99.90% and independent mechanistic evidence of PR-HER2 pathway crosstalk together support advancing this prediction to a structured clinical evaluation.

To proceed, the following is needed:

Safety baseline: Obtain TFDA, EMA, or FDA package insert/SmPC to fulfill drug-level safety screening (key warnings, contraindications, and teratogenicity data)
MOA documentation: Complete DrugBank API query to formally capture trastuzumab mechanism of action for regulatory submission preparation
Philippines regulatory pathway: Initiate FDA Philippines registration planning; consider biosimilar entry strategy given lower access barriers
Patient stratification algorithm: Define HER2 IHC/FISH and PR testing protocol to identify the PR+/HER2+ target population
Cardiac monitoring protocol: Establish LVEF baseline measurement and serial monitoring schedule before and during therapy
Combination strategy planning: Define the optimal co-treatment framework — aromatase inhibitor, fulvestrant, pertuzumab, or CDK4/6 inhibitor — based on metastatic vs. early-stage setting
Drug interaction review: Assess DDI profile when combined with endocrine agents and other targeted therapies planned for the PR+/HER2+ regimen
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.